

PATENT
674523-2006.1

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

1-10. (Cancelled)

11. (Currently amended) The retroviral vector production system according to claim 30, wherein the non-primate lentivirus is equine infectious anemia virus (EIAV).

12-15. (Cancelled)

16. (Currently amended) A non-primate lentivirus-based retroviral particle produced by comprising a retroviral vector obtained from the retroviral vector production system of claim 30, wherein the retroviral particle comprises a non-primate lentivirus genome, gag, pol, and an envelope protein, and wherein the retroviral particle lacks functional Tat.

17. (Previously presented) A cell transfected or transduced with the retroviral particle of claim 16.

18. (Currently amended) A cell transfected or transduced with a retroviral vector obtained from the retroviral vector production system according to claim 30.

19. (Cancelled)

20. (Currently amended) A method for delivery of a nucleotide sequence of interest (NOI) to a target cell comprising introducing into the target cell the [[a]] retroviral vector particle obtained from the retroviral vector production system according to claim 30 into the target cell, wherein the retroviral vector particle comprises an NOI; and whereby the NOI is expressed in the target cell.

21. (Currently amended) A method of transfecting or transducing a cell, comprising contacting said cell with a retroviral vector obtained from the retroviral vector production system according to claim 30, whereby wherein said cell is transfected or transduced by said retroviral vector.

22. (Currently amended) A delivery system in the form of a comprising the retroviral vector particle obtained from the retroviral production system according claim 30, and a pharmaceutically acceptable carrier.

23-29. (Cancelled)

30. (Currently amended) A non-primate lentivirus-based retroviral vector production

PATENT
674523-2006.1

system comprising nucleic acid sequence(s) encoding a non-primate lentivirus genome, gag, pol, and an envelope protein, wherein nucleic acid sequence(s) encoding functional Tat are absent from the system, wherein the lentivirus genome includes a packaging sequence, and wherein said production system produces an infection and transduction competent, non-primate lentivirus-based retroviral vector particle.

31. (New) The retroviral production system according to claim 30, wherein the envelope protein is VSV-G.
32. (New) The retroviral particle according to claim 16, wherein the envelope protein is VSV-G.
33. (New) The retroviral particle according to claim 16, further comprising an NOI.